ETTX Insider Trading

Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 6.50%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Entasis Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Entasis Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Entasis Therapeutics Share Price & Price History

Current Price: $2.19
Price Change: +0.30 (1.20%)
As of 08/5/2022 01:00 AM ET

This chart shows the closing price history over time for ETTX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Entasis Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/11/2022Innoviva, Inc.Major ShareholderBuy7,598,814$2.20$16,717,390.8029,270,476View SEC Filing Icon  
7/8/2022Innoviva, Inc.Major ShareholderBuy11,671,662$2.20$25,677,656.4021,671,662View SEC Filing Icon  
10/19/2021Elizabeth M. KeileyGeneral CounselSell3,759$3.19$11,991.21View SEC Filing Icon  
10/19/2021Manoussos PerrosInsiderSell11,974$3.19$38,197.06View SEC Filing Icon  
6/11/2021Innoviva, Inc.Major ShareholderBuy6,268,975$2.00$12,537,950.00View SEC Filing Icon  
5/3/2021Innoviva, Inc.Major ShareholderBuy3,731,025$2.00$7,462,050.00View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Entasis Therapeutics (NASDAQ:ETTX)

6.91% of Entasis Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ETTX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Entasis Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/16/2022Jane Street Group LLC30,262$67K0.0%N/A0.063%Search for SEC Filing on Google Icon
8/15/2022State Street Corp83,705$0.18M0.0%+107.7%0.175%Search for SEC Filing on Google Icon
8/13/2022Virtu Financial LLC20,027$44K0.0%N/A0.042%Search for SEC Filing on Google Icon
8/13/2022Renaissance Technologies LLC350,345$0.77M0.0%+8.2%0.732%Search for SEC Filing on Google Icon
8/11/2022UBS Group AG12,179$27K0.0%+60.8%0.025%Search for SEC Filing on Google Icon
7/18/2022Deltec Asset Management LLC155,614$0.34M0.1%N/A0.325%Search for SEC Filing on Google Icon
5/18/2022Gabelli Funds LLC59,100$0.11M0.0%N/A0.124%Search for SEC Filing on Google Icon
5/18/2022GABELLI & Co INVESTMENT ADVISERS INC.40,900$76K0.0%N/A0.085%Search for SEC Filing on Google Icon
5/13/2022GABELLI & Co INVESTMENT ADVISERS INC.40,900$76K0.0%N/A0.085%Search for SEC Filing on Google Icon
5/13/2022Gabelli Funds LLC59,100$0.11M0.0%N/A0.124%Search for SEC Filing on Google Icon
5/13/2022Vanguard Group Inc.483,723$0.91M0.0%+7.5%1.011%Search for SEC Filing on Google Icon
2/10/2022Acadian Asset Management LLC55,813$0.12M0.0%+172.0%0.117%Search for SEC Filing on Google Icon
11/16/2021Two Sigma Advisers LP229,000$0.77M0.0%+40.5%0.481%Search for SEC Filing on Google Icon
11/16/2021Two Sigma Investments LP186,230$0.62M0.0%+13.4%0.391%Search for SEC Filing on Google Icon
11/15/2021Alberta Investment Management Corp65,000$0.22M0.0%-50.0%0.136%Search for SEC Filing on Google Icon
11/12/2021Renaissance Technologies LLC312,545$1.04M0.0%-20.2%0.656%Search for SEC Filing on Google Icon
11/9/2021BlackRock Inc.26,619$89K0.0%-18.8%0.056%Search for SEC Filing on Google Icon
8/17/2021Bridgeway Capital Management LLC110,000$0.29M0.0%-8.3%0.233%Search for SEC Filing on Google Icon
8/16/2021Alberta Investment Management Corp130,000$0.35M0.0%N/A0.275%Search for SEC Filing on Google Icon
8/16/2021Occudo Quantitative Strategies LP23,058$62K0.0%-20.6%0.049%Search for SEC Filing on Google Icon
8/16/2021State Street Corp39,205$0.11M0.0%N/A0.083%Search for SEC Filing on Google Icon
8/13/2021Renaissance Technologies LLC391,629$1.05M0.0%-50.2%0.828%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC81,121$0.22M0.0%+53.9%0.171%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.419,997$1.12M0.0%+104.7%0.888%Search for SEC Filing on Google Icon
8/11/2021Susquehanna Fundamental Investments LLC22,094$59K0.0%-47.2%0.047%Search for SEC Filing on Google Icon
5/21/2021Citadel Advisors LLC68,574$0.15M0.0%+26.7%0.184%Search for SEC Filing on Google Icon
5/19/2021Squarepoint Ops LLC91,725$0.20M0.0%+53.8%0.246%Search for SEC Filing on Google Icon
5/18/2021Citadel Advisors LLC68,574$0.15M0.0%+26.7%0.184%Search for SEC Filing on Google Icon
5/14/2021Occudo Quantitative Strategies LP29,031$62K0.0%+101.0%0.078%Search for SEC Filing on Google Icon
5/13/2021Renaissance Technologies LLC786,606$1.68M0.0%+55.3%2.108%Search for SEC Filing on Google Icon
5/12/2021Northern Trust Corp20,874$45K0.0%+77.0%0.056%Search for SEC Filing on Google Icon
5/12/2021Geode Capital Management LLC52,697$0.11M0.0%+99.9%0.141%Search for SEC Filing on Google Icon
4/27/2021Janney Montgomery Scott LLC70,930$0.15M0.0%+13.2%0.190%Search for SEC Filing on Google Icon
2/24/2021Virtu Financial LLC146,128$0.36M0.0%+478.9%0.412%Search for SEC Filing on Google Icon
2/16/2021Squarepoint Ops LLC59,644$0.15M0.0%N/A0.168%Search for SEC Filing on Google Icon
2/12/2021Jaffetilchin Investment Partners LLC11,000$27K0.0%N/A0.031%Search for SEC Filing on Google Icon
2/10/2021Renaissance Technologies LLC506,389$1.25M0.0%+110.3%1.427%Search for SEC Filing on Google Icon
2/9/2021Pivotal bioVenture Partners Investment Advisor LLC1,180,178$2.92M1.0%N/A3.327%Search for SEC Filing on Google Icon
1/25/2021Janney Montgomery Scott LLC62,663$0.16M0.0%+20.0%0.177%Search for SEC Filing on Google Icon
12/11/2020Virtu Financial LLC25,241$51K0.0%N/A0.071%Search for SEC Filing on Google Icon
11/17/2020Paloma Partners Management Co18,891$39K0.0%N/A0.053%Search for SEC Filing on Google Icon
11/17/2020Jane Street Group LLC20,820$42K0.0%N/A0.059%Search for SEC Filing on Google Icon
11/16/2020Blackstone Group Inc568,004$1.16M0.0%-57.9%1.601%Search for SEC Filing on Google Icon
11/13/2020Sofinnova Investments Inc.1,012,408$2.07M0.2%-14.2%2.854%Search for SEC Filing on Google Icon
11/9/2020Caas Capital Management LP579,379$1.18M0.0%N/A1.633%Search for SEC Filing on Google Icon
11/4/2020Raymond James Financial Services Advisors Inc.34,569$71K0.0%+52.3%0.097%Search for SEC Filing on Google Icon
8/31/2020Bridgeway Capital Management Inc.70,000$0.21M0.0%+100.0%0.256%Search for SEC Filing on Google Icon
8/18/2020Blackstone Group Inc1,350,490$4M0.0%-16.8%4.949%Search for SEC Filing on Google Icon
7/23/2020Janney Montgomery Scott LLC54,898$0.16M0.0%+6.5%0.376%Search for SEC Filing on Google Icon
7/17/2020Raymond James Financial Services Advisors Inc.22,700$67K0.0%+12.4%0.155%Search for SEC Filing on Google Icon
5/13/2020Frazier Management LLC1,049,953$2.78M0.3%-22.2%7.185%Search for SEC Filing on Google Icon
2/13/2020Renaissance Technologies LLC25,300$0.13M0.0%+42.9%0.190%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Entasis Therapeutics logo
Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc.
Read More on Entasis Therapeutics

Today's Range

Now: $2.19
Low: $2.19
High: $2.19

50 Day Range

MA: $2.19
Low: $2.18
High: $2.20

52 Week Range

Now: $2.19
Low: $1.40
High: $3.88

Volume

800 shs

Average Volume

239,104 shs

Market Capitalization

$104.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.33

Who are the company insiders with the largest holdings of Entasis Therapeutics?

Entasis Therapeutics' top insider shareholders include:
  1. Innoviva, Inc (Major Shareholder)
Learn More about top insider investors at Entasis Therapeutics.